EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sodium butyrate ameliorates renal tubular lipid accumulation through a protein phosphatase 2A/transcription factor EB axis in diabetic nephropathy

Jiayin Tao, Sinan Ai, Yaoxian Wang, Yuning Liu, Jingwei Zhou, Qingqing Liu, Xu Wang, Danting Li, Xin Li, Lin Wang, Jinyi Hou, Liang Peng und 1 weitere

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Jiayin Tao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Butyric Acid, Lipid Metabolism, Kidney Tubules. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing University of Chinese Medicine's 2022 Basic Research Business Fee Disclosure Leading Project, Beijing Research Ward Construction Clinical Research Project, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Extensive evidence indicates that lipid accumulation causes renal tubular injury, which further contributes to diabetic nephropathy (DN) progression. Short‐chain fatty acids (SCFAs) play an important role in the maintenance of cellular metabolic health. Previous studies have found a significant deficiency of SCFAs in DN patients, although their effects on lipid accumulation in renal tubules have not been investigated. We have investigated the effect of sodium butyrate (NaB), one of the most abundant SCFAs, on renal tubular lipid accumulation in DN and elucidated its underlying protective mechanisms. Experimental Approach The effects of NaB were investigated on renal tubular lipid accumulation in vitro (using a glucolipotoxicity‐treated HK‐2 cell line) and DN progression in vivo (with streptozotocin injection combined with a high‐fat diet in C57BL/6J mice). RNA sequencing, surface plasmon resonance, pulldown MS assay, and molecular docking were applied to explore specific molecular mechanisms. Key Results Our findings revealed that serum butyrate levels were reduced in DN patients and inversely correlated with DN severity. NaB supplementation improved renal tubular lipid accumulation and injury in HK‐2 cells and DN mice. The protective effects of NaB were largely abrogated in kidney‐specific Tfeb knockout mice. NaB directly interacted with PPP2R1A to promote the formation and activation of PP2A heterotrimers, thereby facilitating the dephosphorylation of TFEB and promoting lipophagy. Conclusions and Implications NaB functions as a PP2A‐TFEB axis activator to restore lipophagy and ameliorate lipid accumulation in tubular epithelial cells, pointing to NaB as a promising protective agent against renal injury in DN patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesButyric AcidLipid MetabolismKidney TubulesProtein Phosphatase 2Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsAnimalsHumansMice, Inbred C57BLMaleMiceMice, KnockoutCell LineDiabetes Mellitus, ExperimentalMiddle AgedFemale

Stichwörter der Autor:innen

TFEBdiabetic nephropathylipophagyrenal lipid accumulationsodium butyrate

Substanzen

Butyric AcidProtein Phosphatase 2Basic Helix-Loop-Helix Leucine Zipper Transcription Factors

Autor:innen und Institutionen

  • Department of Nephrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Renal Research Institution of Beijing University of Chinese Medicine, and Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese…
  • Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Medical Science, China-Japan Friendship Hospital, Beijing, China.
  • Henan University of Chinese Medicine, Zhengzhou, China.

Förderung

  • Beijing University of Chinese Medicine's 2022 Basic Research Business Fee Disclosure Leading Project
  • Beijing Research Ward Construction Clinical Research Project
  • National High Level Hospital Clinical Research Funding
  • National Natural Science Foundation of China
  • Beijing Municipal Natural Science Foundation of China

Zitieren

APA

Tao, J., Ai, S., Wang, Y., Liu, Y., Zhou, J., Liu, Q., Wang, X., Li, D., Li, X., Wang, L., Hou, J., Peng, L., & Wang, Z. (2026). Sodium butyrate ameliorates renal tubular lipid accumulation through a protein phosphatase 2A/transcription factor EB axis in diabetic nephropathy. British Journal of Pharmacology. https://doi.org/10.1111/bph.70261

Vancouver

Tao J, Ai S, Wang Y, Liu Y, Zhou J, Liu Q, et al. Sodium butyrate ameliorates renal tubular lipid accumulation through a protein phosphatase 2A/transcription factor EB axis in diabetic nephropathy. British Journal of Pharmacology. 2026. doi:10.1111/bph.70261

BibTeX
@article{Tao2026,
  author = {Tao, Jiayin and Ai, Sinan and Wang, Yaoxian and Liu, Yuning and Zhou, Jingwei and Liu, Qingqing and Wang, Xu and Li, Danting and Li, Xin and Wang, Lin and Hou, Jinyi and Peng, Liang and Wang, Zhen},
  title = {Sodium butyrate ameliorates renal tubular lipid accumulation through a protein phosphatase 2A/transcription factor EB axis in diabetic nephropathy},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70261}
}
Kostenlos starten →